{
    "clinical_study": {
        "@rank": "20111", 
        "brief_summary": {
            "textblock": "The primary goal of this study is evaluate T cell immune status and immune reconstitution\n      and the association with specific cytokines in patients with newly diagnosed HGGs undergoing\n      the standard RT/TMZ and adjuvant TMZ."
        }, 
        "brief_title": "Prospective Evaluation of T-cell Immune Status in Patients With Newly Diagnosed High Grade Gliomas", 
        "condition": "High Grade Glioma", 
        "condition_browse": {
            "mesh_term": "Glioma"
        }, 
        "detailed_description": {
            "textblock": "Numbers of T-cell subtypes at six time points in patients with newly diagnosed HGGs\n      undergoing standard RT/TMZ and adjuvant TMZ:\n\n        1. Baseline within 2 weeks before initiation of RT/TMZ\n\n        2. At the end of RT/TMZ approximately week 6\n\n        3. Before adjuvant TMZ approximately week 10\n\n        4. After 2 cycle of TMZ approximately week 18\n\n        5. After 4 cycle of TMZ approximately week 26\n\n        6. Three month after last cycle of TMZ\n\n      Secondary Endpoints\n\n        1. Changes in serial T cell subtypes and cytokines levels\n\n        2. Incidence of lymphopenia related infections\n\n        3. Changes in T-cell numbers and subtypes with TMZ administration\n\n        4. Overall survival"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients must be at least 18 years of age.\n\n          2. Patients must have histologically confirmed new diagnosed high grade glioma by\n             pathology (WHO grade III and IV).\n\n          3. Patients proposed post-operative treatment plan must include standard radiation and\n             temozolomide.\n\n          4. Patients must have a Karnofsky performance status \u2265 60% (i.e. the patient must be\n             able to care for himself/herself with occasional help from others).\n\n          5. Patients must be able to provide written informed consent.\n\n          6. Steroid use is allowed.\n\n        Exclusion Criteria:\n\n        1. Patients with HIV are excluded."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "outpatient or inpatient  and community clinic patients"
            }
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02041611", 
            "org_study_id": "J1389", 
            "secondary_id": "NA_00086826"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "WHO grade III and IV", 
        "lastchanged_date": "January 17, 2014", 
        "location": {
            "contact": {
                "last_name": "Stuart A Grossman, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21231"
                }, 
                "name": "Johns Hopkins"
            }, 
            "investigator": {
                "last_name": "Jian Campian, MD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Prospective Evaluation of T-cell Immune Status in Patients With Newly Diagnosed High Grade Gliomas", 
        "overall_contact": {
            "email": "grossman@jhmi.edu", 
            "last_name": "Stuart A Grossman, MD", 
            "phone": "410-955-8837"
        }, 
        "overall_contact_backup": {
            "email": "jfisher@jhmi.edu", 
            "last_name": "Joy D Fisher, MA", 
            "phone": "410-955-3657"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "baseline approx 6wks approx 10wks aprox 18wks approx 26wks 3 months after last cycle of TMZ", 
            "measure": "Changes in T Cell subtypes and cytokines as a function of treatment", 
            "safety_issue": "No", 
            "time_frame": "6 time points in pts undergoing standard RT/TMZ and adjuvant TMZ"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02041611"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Sidney Kimmel Comprehensive Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sidney Kimmel Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}